Child Neurology Society Annual Meeting (CNS)

Study results show that deflazacort tops prednisone across multiple checkpoints in patients with Duchenne muscular dystrophy.

Epilepsy-specific TRAQ questionnaire shows high validity in pediatric epilepsy patients transitioning to adult epilepsy care.

Data presented at the Child Neurology Society Annual Meeting suggest that the safety and efficacy of cannabidiol (Epidiolex; GW Pharmaceuticals) is maintained through 72 weeks of treatment for patients with LGS.

The drug recently gained FDA approval for treatment of lower limb spasticity in pediatric patients without cerebral palsy, in which it is associated with improved functional outcomes.

A pooled analysis of 2 phase 3 trials of fenfluramine demonstrate the clinical potential of the drug for patients with Dravet syndrome.

The professor and head of the Department of Neurology and Rehabilitation at the University of Illinois at Chicago spoke about how data can better inform epilepsy care.

The Carolyn and Matthew Bucksbaum Professor of Clinical Ethics at the University of Chicago spoke about the ethical considerations of spinal muscular atrophy and its treatment.

The clinical professor in pediatric neurology and director of regional neurology services at Children's Hospital Colorado shared her thoughts on why epilepsy is the perfect paradigm to implement telemedicine.

The Pediatric Movement Disorders Neurologist at UT Southwestern recommends that when encountering a patient with a movement disorder to organize your thought process in 3 steps.

The Sidney Carter Professor of Neurology at Columbia University Medical Center spoke about the 127 year history of spinal muscular atrophy and how basic science has led to exciting developments.